Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Short-term Investments (2016 - 2025)

CytomX Therapeutics' Short-term Investments history spans 11 years, with the latest figure at $124.4 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 98.79% year-over-year to $124.4 million; the TTM value through Dec 2025 reached $124.4 million, up 98.79%, while the annual FY2025 figure was $124.4 million, 98.79% up from the prior year.
  • Short-term Investments reached $124.4 million in Q4 2025 per CTMX's latest filing, up from $109.4 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $168.1 million in Q3 2023 to a low of $5000.0 in Q3 2021.
  • Average Short-term Investments over 5 years is $94.2 million, with a median of $99.3 million recorded in 2022.
  • Peak YoY movement for Short-term Investments: plummeted 100.0% in 2021, then skyrocketed 1984980.0% in 2022.
  • A 5-year view of Short-term Investments shows it stood at $99.7 million in 2021, then fell by 0.44% to $99.3 million in 2022, then soared by 58.52% to $157.3 million in 2023, then tumbled by 60.23% to $62.6 million in 2024, then surged by 98.79% to $124.4 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Short-term Investments are $124.4 million (Q4 2025), $109.4 million (Q3 2025), and $109.0 million (Q2 2025).